Treatment of idiopathic oligozoospermia with tamoxifen — a randomized controlled study
The DOI matches its Crossref record.
Abstract
Summary: There is no conclusive evidence of the usefulness of tamoxifen in the treatment of idiopathic oligozoospermia (OAT‐syndrome), as it has been used mostly in uncontrolled studies. We herein report on the controlled treatment of OAT‐syndrome with tamoxifen versus placebo following a randomized design. Seventy‐six men with sperm counts of 2–20 times 10 6 ml‐1, sperm motility of 20–50%, and sperm morphology (abnormal cells) between 50 and 80% were involved in the study. Patients with varicocele, a history of testicular maldescent or genital inflammation were excluded. Thirty‐nine patients received tamoxifen (30 mg daily), 37 patients placebo. There was a statistically significant increase in the mean serum testosterone level after treatment in the tamoxifen‐treated group (from 4.9 ± 1.9 to 7.9 ± 3.6 ng ml‐1) in comparison to the placebo group (5.3 ± 2.0 and 5.6 ± 2.0 ng ml‐1).serum FSH levels increased slightly in the tamoxifen group (from 6.8 ± 4.1 to 7.3 ± 4.8 mU ml‐1), but this was not statistically significant in comparison to the placebo group (from 5.9 ± 3.9 to 5.2 ± 3.5 mU ml‐1). Serum levels of LH did not show any differences between groups. The sperm count increased during treatment from 9.3 ± 11.7 to 11.4 ± 13.7 times 10 6 ml‐1 in the tamoxifen group and from 9.1 +‐ 7.1 to 9.3 +‐ 8.8 * 10‐1 in the placebo group; this difference did not reach statiscal significance. The percentage of motile and abnormal sperm was not different between the two treatment groups. In 5 out 37 of the tamoxifen‐treated patients and in 3 out 39 patients of the placebo group, a conception in the female partner was recorded within 9 months after treatment. The fact that the difference in sperm output and pregnancy rate between tamoxifen‐and placebo‐treated men is not statistically significant in out study might be due to the small size of the groups, and a more extensive study might overcome this problem.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
A role for oestrogens in the male reproductive system
Hess, R. A., Bunick, D., Lee, K.-H., Bahr, J., Taylor, J. A., Korach, K. S., & Lubahn, D. B. (1997) · Nature · doi:10.1038/37352 · Cited by 879
The Importance of Quality of Primary Studies in Producing Unbiased Systematic Reviews
Khan, K. S. (1996) · Archives of Internal Medicine · doi:10.1001/archinte.156.6.661 · Cited by 328
Marmar, J. L., & Kim, Y. (1994) · Journal of Urology · doi:10.1016/s0022-5347(17)32521-1 · Cited by 264
Chua, M. E., Escusa, K. G., Luna, S., Tapia, L. C., Dofitas, B., & Morales, M. (2013) · Andrology · doi:10.1111/j.2047-2927.2013.00107.x · Cited by 183
Cannarella, R., Condorelli, R. A., Mongioì, L. M., Barbagallo, F., Calogero, A. E., & La Vignera, S. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1615057 · Cited by 91
Metadata
- Authors
- KRAUSE, W., HOLLAND‐MORITZ, H., & SCHRAMM, P.
- Venue
- International Journal of Andrology
- Publisher
- Wiley
- Published
- 1992-02
- Volume
- 15
- Issue
- 1
- Pages
- 14-18
- ISSN
- 0105-6263 (ISSN-L)
- 1365-2605
- OpenAlex
- W2159242914
- Cited by
- 65
- References
- 0
- FWCI
- 3.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of idiopathic oligozoospermia with tamoxifen — a randomized controlled study. https://app.cochat.ai/papers/10.1111/j.1365-2605.1992.tb01110.x
- The paper
- KRAUSE, W., HOLLAND‐MORITZ, H., & SCHRAMM, P. (1992). Treatment of idiopathic oligozoospermia with tamoxifen — a randomized controlled study. International Journal of Andrology. https://doi.org/10.1111/j.1365-2605.1992.tb01110.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.